Data Insights

Ulevostinag by Merck for Cutaneous T-Cell Lymphoma: Likelihood of Approval

Ulevostinag is under clinical development by Merck and currently in Phase I for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ulevostinag in Cutaneous T-Cell Lymphoma

Data Insights

Risk adjusted net present value: What is the current valuation of Merck's Ulevostinag?

Ulevostinag is a small molecule commercialized by Merck, with a leading Phase I program in Anaplastic Thyroid Cancer. According to...

Net Present Value Model: Merck & Co Inc's Ulevostinag

Data Insights

Ulevostinag by Merck for Lymphoma: Likelihood of Approval

Ulevostinag is under clinical development by Merck and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Ulevostinag in Lymphoma

Data Insights

Ulevostinag by Merck for Hepatocellular Carcinoma: Likelihood of Approval

Ulevostinag is under clinical development by Merck and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Ulevostinag in Hepatocellular Carcinoma

Data Insights

Ulevostinag by Merck for Solid Tumor: Likelihood of Approval

Ulevostinag is under clinical development by Merck and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Ulevostinag in Solid Tumor

Data Insights

Ulevostinag by Merck for Hypopharyngeal Cancer: Likelihood of Approval

Ulevostinag is under clinical development by Merck and currently in Phase I for Hypopharyngeal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Ulevostinag in Hypopharyngeal Cancer

Data Insights

Ulevostinag by Merck for Laryngeal Cancer: Likelihood of Approval

Ulevostinag is under clinical development by Merck and currently in Phase I for Laryngeal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Ulevostinag in Laryngeal Cancer

Data Insights

Ulevostinag by Merck for Oropharyngeal Cancer: Likelihood of Approval

Ulevostinag is under clinical development by Merck and currently in Phase I for Oropharyngeal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Ulevostinag in Oropharyngeal Cancer

Data Insights

Ulevostinag by Merck for Anaplastic Thyroid Cancer: Likelihood of Approval

Ulevostinag is under clinical development by Merck and currently in Phase I for Anaplastic Thyroid Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ulevostinag in Anaplastic Thyroid Cancer

Data Insights

Ulevostinag by Merck for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Ulevostinag is under clinical development by Merck and currently in Phase I for Oral Cavity (Mouth) Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ulevostinag in Oral Cavity (Mouth) Cancer

Data Insights

Ulevostinag by Merck for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Ulevostinag is under clinical development by Merck and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....

Likelihood of Approval and Phase Transition Success Rate Model - Ulevostinag in Head And Neck Squamous Cell Carcinoma (HNSC)